Sage Therapeutics

Traded on the St. Petersburg Stock Exchange
Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain.
Sage Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Sage Therapeutics balance sheet

Report period2018 2019 2020 2021 2022 Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Sage Therapeutics cash flows

Report period2018 2019 2020 2021 2022 Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Sage Therapeutics multipliers

Report period2018 2019 2020 2021 2022 Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Sage Therapeutics profitability

Report period2018 2019 2020 2021 2022 Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Sage Therapeutics assets
Sage Therapeutics cash flows

Sage Therapeutics shares

TickerNameTypeNominal valueISINPrice
SAGE:USSAGE Therapeutics, Inc.Common share-US78667J1088$13.33
Sage Therapeutics news
03.05.2022
Sage Therapeutics' GAAP loss for 3 months of 2022 was $122.055 million, up 27.5% from $95.764 million in the prior year. Revenue decreased 0.1% to $1,582 million from $1,583 million a year earlier.
Source: {source} pictogram investor.sagerx.com
Pictogram next
24.02.2022
Sage Therapeutics reported a GAAP loss of $457.892 million for 2021, compared to a profit of $606.073 million in the previous year. Revenue declined 18.6 times to $0.06 billion from $1.114 billion a year earlier.
Source: {source} pictogram investor.sagerx.com
Pictogram next
02.11.2021
Sage Therapeutics' GAAP loss for 9M 2021 was $333.18 million, down 9.7% from $368.822 million in the prior year. Revenues fell 6.9% to $4.666 million from $5.014 million a year earlier.
Source: {source} pictogram investor.sagerx.com
Pictogram next
03.08.2021
Sage Therapeutics' GAAP loss for the six months of 2021 was $203.009 million, down 22.8% from $263.087 million in the prior year. Revenue declined 4.4% to $3.226 billion from $3.375 billion a year earlier.
Source: {source} pictogram investor.sagerx.com
Pictogram next
All Sage Therapeutics news
General information
Company nameSage Therapeutics
Tags#biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address215 FIRST STREET CAMBRIDGE MA 02142 617-299-8380
Mailing address215 FIRST STREET CAMBRIDGE MA 02142
Websitewww.sagerx.com
Information disclosurewww.sec.gov